Insulet Co. (NASDAQ:PODD) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Insulet Co. (NASDAQ:PODD) have been given a consensus recommendation of “Moderate Buy” by the fourteen analysts that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $242.29.

A number of equities analysts recently commented on PODD shares. Raymond James raised their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. UBS Group raised their price objective on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Barclays upped their target price on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. Canaccord Genuity Group raised their price target on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Finally, Piper Sandler upped their price objective on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th.

Insulet Price Performance

Insulet stock opened at $241.32 on Wednesday. The company’s 50 day simple moving average is $228.23 and its 200-day simple moving average is $202.16. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. Insulet has a 1 year low of $151.56 and a 1 year high of $243.98. The company has a market capitalization of $16.92 billion, a price-to-earnings ratio of 43.88, a price-to-earnings-growth ratio of 4.40 and a beta of 1.22.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The firm had revenue of $488.50 million during the quarter, compared to analysts’ expectations of $488.00 million. During the same period in the previous year, the firm earned $0.38 EPS. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, equities research analysts expect that Insulet will post 3.04 earnings per share for the current year.

Hedge Funds Weigh In On Insulet

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PODD. Diversified Trust Co lifted its position in shares of Insulet by 90.9% during the 2nd quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock worth $1,842,000 after buying an additional 4,348 shares during the last quarter. SG Americas Securities LLC boosted its stake in Insulet by 349.3% in the first quarter. SG Americas Securities LLC now owns 29,575 shares of the medical instruments supplier’s stock valued at $5,069,000 after acquiring an additional 22,993 shares in the last quarter. Duality Advisers LP grew its holdings in shares of Insulet by 89.4% during the first quarter. Duality Advisers LP now owns 19,131 shares of the medical instruments supplier’s stock worth $3,279,000 after purchasing an additional 9,029 shares during the last quarter. Diversify Advisory Services LLC acquired a new stake in shares of Insulet during the first quarter worth about $1,043,000. Finally, Intech Investment Management LLC lifted its holdings in shares of Insulet by 113.8% in the 1st quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock valued at $1,140,000 after purchasing an additional 3,539 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.